quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:40:50·884d
INSIDERFiling
Everest Re Group Ltd. logo

Williamson James Allan covered exercise/tax liability with 646 shares, decreasing direct ownership by 6% to 11,049 units (SEC Form 4)

RE· Everest Re Group Ltd.
Finance
Original source

Companies

  • RE
    Everest Re Group Ltd.
    Finance

Recent analyst ratings

  • Jul 7UpdateRaymond James$450.00
  • Jun 21UpdateCitigroup$406.00
  • Jun 20UpdateMorgan Stanley$429.00
  • Feb 2UpdateRaymond James$385.00
  • Jan 20UpdateBMO Capital Markets$380.00
  • Nov 9UpdateMorgan Stanley$320.00

Related

  • INSIDER800d
    Singer Roger M. bought $178,605 worth of shares (500 units at $357.21), increasing direct ownership by 3% to 16,920 units (SEC Form 4)
  • INSIDER800d
    Graf John A bought $247,941 worth of shares (695 units at $356.75), increasing direct ownership by 5% to 14,754 units (SEC Form 4)
  • 13D/G800d
    SEC Form SC 13G/A filed by Everest Re Group Ltd. (Amendment)
  • INSIDER801d
    Karmilowicz Mike bought $100,430 worth of shares (285 units at $352.39), increasing direct ownership by 3% to 10,586 units (SEC Form 4)
  • INSIDER801d
    Kociancic Mark bought $349,000 worth of shares (1,000 units at $349.00), increasing direct ownership by 4% to 25,733 units (SEC Form 4)
  • INSIDER801d
    Williamson James Allan bought $246,750 worth of shares (700 units at $352.50), increasing direct ownership by 6% to 11,749 units (SEC Form 4)
  • INSIDER801d
    Andrade Juan C bought $251,798 worth of shares (720 units at $349.72), increasing direct ownership by 1% to 51,220 units (SEC Form 4)
  • SEC806d
    Everest Re Group Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022